Dr. Shruti Mehta, a professor in the department of epidemiology at the Johns Hopkins Bloomberg School of Public Health, has received a $4.3 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the individual- and population-level impact of a strategy to deliver hepatitis C virus (HCV) treatment to people who inject drugs (PWID) in India. Dr. Mehta’s research team includes Dr. Sunil Solomon, an associate professor of medicine in the division of infectious diseases at the Johns Hopkins University School of Medicine, and other investigators at Johns Hopkins, the University of California San Diego and the YR Gaitonde Center for AIDS Research and Education in India.
The World Health Organization has set goals for global HCV elimination by 2030. Global elimination, measured as a 65 percent reduction in mortality and 90 percent reduction in HCV incidence, can only be achieved if all populations are reached including those who are hardest to reach such as PWID in low- and-middle-income settings.
To evaluate the potential for achieving HCV elimination targets among PWID in India, HCV treatment will be integrated within existing HIV prevention and treatment service centers which cater to PWID across seven cities in India. The team will assess the impact of a strategy to tailor treatment support to patient needs while conserving resources through a novel precision clinical trial approach.
Dr. Mehta’s research focuses on prevention and treatment of HIV and HCV infection among people who inject drugs.Tags: Friday Letter Submission, Publish on August 23